Q-omics provides the consensus-scored AKNAD1 profile across patient tissues and cancer cell-line models. AKNAD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AKNAD1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, AKNAD1 RNA expression shows 16,357 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where AKNAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKNAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKNAD1 survival associations across molecular data types. AKNAD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKNAD1 RNA expression–survival associations across cancer types. High AKNAD1 expression shows unfavorable associations in KIRC, KICH, KIRP, LIHC and LGG, but favorable associations in COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AKNAD1 RNA expression.
This table summarizes AKNAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for AKNAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKNAD1 shows lower tumor expression in THCA, UCEC and LUAD and higher tumor expression in HNSC, COAD and KICH. The THCA box plot shows higher AKNAD1 RNA expression in normal versus tumor tissue (log2 FC = −0.179, t-test p < 0.001).
This table shows molecular features associated with AKNAD1 in patient tissues and cancer cell lines. In patient samples, AKNAD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AKNAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
